Drug intelligence / Profile preview

APH-1505

Development stage: Preclinical
Lead developer: Aphios Pharma
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

APH-1505 is an oral, extended-release nanoformulation of cannabidiol (CBD) being developed by Aphios Corporation (through its subsidiary Aphios Pharma) for the treatment of refractory epilepsy. The drug utilizes Aphios' proprietary SFS-PNS™ platform to encapsulate CBD within biodegradable polymer nanoparticles, which is intended to provide sustained release, enhance bioavailability, and improve the side-effect profile compared to conventional CBD treatments. APH-1505 targets the endocannabinoid system, specifically the CB1 and CB2 receptors, to modulate neuronal activity and reduce seizure frequency in patients with drug-resistant forms of epilepsy.

Other names: cannabidiol nanoformulationnanoencapsulated CBD

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on APH-1505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-1505.

Explore the full profile